This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for BeneFIX® (nonacog alfa) and ReFacto AF® (moroctocog alfa) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

Pfizer helps to find practical approaches to haemophilia care through partnering with various organisations.

Pfizer has partnered with various organisations to help find practical approaches to haemophilia care

  • Pfizer is committed to the improvement of long-term outcomes for people with haemophilia and the support they receive to manage their conditions
  • Through scientific collaboration and long-term investment in new haemophilia therapies, we aim to advance the treatment and address the unmet needs of people with haemophilia

Treatment of haemophilia

Haemophilia is quite rare; about 1 in 10,000 people are born with it1. A primary aim of care in haemophilia is to prevent and treat bleeding with the deficient clotting factor2:

  • On-demand: Treatment given at the time of clinically evident bleeding or before, during or after an activity or intervention likely to increase the risk of bleeding
  • Prophylaxis: Treatment given regularly in order to prevent anticipated bleeding

Milestones in Pfizer Haemophilia

Pfizer continue to invest in the research and development of haemophilia treatment. View our Pfizer timeline of milestones in haemophilia, spanning from the early 1990's.

Explore more

What is haemophilia?

Find out more

Explore our range of educational materials for children with haemophilia

Click here

​​​​​​​References
  1. World Federation of Hemophilia. What is Hemophilia? Available at: https://elearning.wfh.org/elearningcentres/introduction-to-hemophilia/#what_is_hemophilia (Accessed January 2020).
  2. Srivastava A et al. Guidelines for the management of hemophilia. 2013;19, e1-e47
  3. Funding Universe. Genetics Institute, Inchistory. Available at: http://www.fundinguniverse.com/company-histories/genetics-institute-inc-... (Accessed January 2020).
  4. CenterWatch. BeneFIX(coagulation Factor IX (recombinant)). Available at: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/3222-benefix-coagulation-factor-ix-recombinant (Accessed January 2020)
  5. Kelley B et al. An improved manufacturing process for Xyntha/ ReFactoAF. Haemophilia 2010;16(5):717–725.
  6. ReFacto AF (moroctocog alfa) Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/6558/smpc
  7. BioSpace. Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX, published 26th March 2007. Available at:  https://www.biospace.com/article/releases/wyeth-receives-fda-approval-for-new-benefix-features-that-provide-hemophilia-b-patients-a-simpler-and-more-convenient-preparation-process-for-recombin/ (Accessed January 2020).
  8. Lambert T et al. Reformulated BeneFIX: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007;13(3):233–243.
  9. European Medicines Agency. Assessment report for ReFacto AF. 2009. Doc ref: EMEA/55167/2009. Available at: https://www.ema.europa.eu/en/documents/variation-report/refacto-af-h-c-232-ii-0059-0068-epar-assessment-report-variation_en.pdf (Accessed October 2020).
  10. BeneFIX (nonacog alfa) Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/6157/smpc
  11. European Medicines Agency. BeneFIX EPAR – procedural steps taken and scientific information after the authorisation. Available at: https://www.ema.europa.eu/en/documents/procedural-steps-after/benefix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf (Accessed October 2020).
  12. Pfizer.co.uk. The Rare Disease Consortium. Available at: https://www.pfizer.com/partnering/areas_of_interest/rare_diseases (Accessed January 2020).
  13. Electronic medicines compendium. ReFacto AF Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/product/7956/pil
  14. Electronic medicines compendium. BeneFIX Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/product/6157/pil
PP-BEN-GBR-0450. March 2021

BeneFIX

For your patients with haemophilia B

Find out more

ReFacto AF

For your patients with haemophilia A

Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No